Omalizumab for treatment of allergic rhinitis

Expert Opinion on Biological Therapy

Volumn 13, Issue 6, 2013, Pages 933-945

  Vashisht, Priyanka ^a   Casale, Thomas ^a  

^a CREIGHTON UNIVERSITY   (United States)

Author keywords

Allergic rhinitis; Anti IgE; IgE; Omalizumab

Indexed keywords

ANTIHISTAMINIC AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CONTACT ALLERGEN; CORTICOSTEROID; DECONGESTIVE AGENT; HISTAMINE; IMMUNOGLOBULIN E; IPRATROPIUM BROMIDE; KININ; LEUKOTRIENE; MONTELUKAST; OMALIZUMAB; PLACEBO; PROSTAGLANDIN; PROTEINASE; ANTIALLERGIC AGENT; ANTIIDIOTYPIC ANTIBODY; MONOCLONAL ANTIBODY;

ALLERGIC AIRWAY INFLAMMATION; ALLERGIC ASTHMA; ALLERGIC RHINITIS; ALOPECIA; ANAPHYLAXIS; ANTIGEN BINDING; ANTIGEN EXPRESSION; ARTHRALGIA; ARTICLE; BASOPHIL; BRONCHOSPASM; CELL INFILTRATION; COUGHING; CYTOKINE RELEASE; DENDRITIC CELL; DIARRHEA; DISTRIBUTION VOLUME; DIZZINESS; DRUG BLOOD LEVEL; DRUG COST; DRUG EFFICACY; DRUG ELIMINATION; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; FAINTNESS; FLUSHING; GRANULOMATOUS VASCULITIS; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOTHERAPY; INFLUENZA; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE REACTION; MAST CELL; MYALGIA; NASAL LAVAGE; NAUSEA; NOSE OBSTRUCTION; ORTHOSTATIC HYPOTENSION; PARASITOSIS; PARESTHESIA; PATHOPHYSIOLOGY; PHARYNGITIS; RECOMMENDED DRUG DOSE; RESPIRATORY TRACT INFLAMMATION; RHINORRHEA; SERUM SICKNESS; SIDE EFFECT; SINUS CONGESTION; THROMBOCYTOPENIA; TISSUES; UPPER ABDOMINAL PAIN; URTICARIA; VASCULITIS; ANIMAL; IMMUNOLOGY; RHINITIS, ALLERGIC, PERENNIAL; RHINITIS, ALLERGIC, SEASONAL; TREATMENT OUTCOME;

ANIMALS; ANTI-ALLERGIC AGENTS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL, HUMANIZED; HUMANS; RHINITIS, ALLERGIC; RHINITIS, ALLERGIC, PERENNIAL; RHINITIS, ALLERGIC, SEASONAL; TREATMENT OUTCOME;

EID: 84877897448     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2013.795943     Document Type: Article

References (77)

1. Bousquet J, Khaltaev N, Cruz AA, et al. Allergic rhinitis and sits impact on asthma (ARIA) 2008 update (in collaboration with the world health organization, GA(2)LEN and AllerGen). Allergy 2008;63(Suppl 86):8-160
2. Lundback B. Epidemiology of rhinitis and asthma. Clin Exp Allergy 1998;28(Suppl 2):3-10
3. Malone DC, Lawson KA, Smith DH, et al. A cost of illness study of allergic rhinitis in the united states. J Allergy Clin Immunol 1997;99:22-7
4. Fineman SM. The burden of allergic rhinitis: Beyond dollars and cents. Ann Allergy Asthma Immunol 2002;88:2-7
5. . 5. Price D, Zhang Q, Kocevar VS, et al. Effect of a concomitant diagnosis of allergic rhinitis on asthma-related health care use by adults. Clin Exp Allergy 2005;35:282-7
6. Bousquet J, Gaugris S, Kocevar VS, et al. Increased risk of asthma attacks and emergency visits among asthma patients with allergic rhinitis: A subgroup analysis of the investigation of montelukast as a partner agent for complementary therapy [corrected]. Clin Exp Allergy 2005;35:723-7
7. Corren J, Manning BE, Thompson SF, et al. Rhinitis therapy and the prevention of hospital care for asthma: A case-control study. J Allergy Clin Immunol 2004;113:415-19
8. Naclerio RM, Meier HL, Kagey-Sobotka A, et al. Mediator release after nasal airway challenge with allergen. Am Rev Respir Dis 1983;128:597-602
9. Bachert C, Wagenmann M, Hauser U. Proinflammatory cytokines: Measurement in nasal secretion and induction of adhesion receptor expression. Int Arch Allergy Immunol 1995;107:106-8
10. White MV, Kaliner MA. Mediators of allergic rhinitis. J Allergy Clin Immunol 1992;90:699-704
11. Stanworth DR. Immunochemical mechanisms of immediate-type hypersensitivity reactions. Clin Exp Immunol 1970;6:1-12
12. Mandhane SN, Shah JH, Thennati R. Allergic rhinitis: An update on disease, present treatments and future prospects. Int Immunopharmacol 2011;11:1646-62 . Treatment review
13. Berger WE. Treatment update: Allergic rhinitis. Allergy Asthma Proc 2001;22:191-8
14. Conner BL, Georgitis JW. Practical diagnosis and treatment of allergic and nonallergic rhinitis. Prim Care 1987;14:457-73
15. van Cauwenberge P. Management of rhinitis-the specialist's opinion. Clin Exp Allergy 1998;28(Suppl 6):29-33
16. Okubo K, Gotoh M, Shimada K, et al. Fexofenadine improves the quality of life and work productivity in japanese patients with seasonal allergic rhinitis during the peak cedar pollinosis season. Int Arch Allergy Immunol 2005;136:148-54
17. Simons FE, Simons KJ. The pharmacology and use of H1-receptor-antagonist drugs. N Engl J Med 1994;330:1663-70
18. Kita H, Jorgensen RK, Reed CE, et al. Mechanism of topical glucocorticoid treatment of hay fever: IL-5 and eosinophil activation during natural allergen exposure are suppressed, but IL-4, IL-6, and IgE antibody production are unaffected. J Allergy Clin Immunol 2000;106:521-9
19. Lipworth BJ. Emerging role of antileukotriene therapy in allergic rhinitis. Clin Exp Allergy 2001;31:1813-21
20. Ramey JT, Bailen E, Lockey RF. Rhinitis medicamentosa. J Investig Allergol Clin Immunol 2006;16:148-55
21. Handelman NI, Friday GA, Schwartz HJ, et al. Cromolyn sodium nasal solution in the prophylactic treatment of pollen-induced seasonal allergic rhinitis. J Allergy Clin Immunol 1977;59:237-42
22. Pawankar R, Bunnag C, Khaltaev N, et al. Allergic rhinitis and its impact on asthma in asia pacific and the ARIA update 2008. World Allergy Organ J 2012;5:S212-17
23. Blanc PD, Trupin L, Eisner M, et al. The work impact of asthma and rhinitis: Findings from a population-based survey. J Clin Epidemiol 2001;54:610-18
24. Incorvaia C, Masieri S, Berto P, et al. Specific immunotherapy by the sublingual route for respiratory allergy. Allergy Asthma Clin Immunol 2010;6:29,1492-6-29
25. Hermelingmeier KE, Weber RK, Hellmich M, et al. Nasal irrigation as an adjunctive treatment in allergic rhinitis: A systematic review and meta-analysis. Am J Rhinol Allergy 2012;26:e119-25
26. Ishizaka K, Ishizaka T, Terry WD. Antigenic structure of gamma-E-globulin and reaginic antibody. J Immunol 1967;99:849-58
27. Shields RL, Whether WR, Zioncheck K, et al. Inhibition of allergic reactions with antibodies to IgE. Int Arch Allergy Immunol 1995;107:308-12
28. Easthope S, Jarvis B. Omalizumab. Drugs 2001;61:253,60; discussion 261
29. Presta LG, Lahr SJ, Shields RL, et al. Humanization of an antibody directed against IgE. J Immunol 1993;151:2623-32
30. Liu J, Lester P, Builder S, Shire SJ. Characterization of complex formation by humanized anti-IgE monoclonal antibody and monoclonal human IgE. Biochemistry 1995;34:10474-82
31. Brownell J, Casale TB. Anti-IgE Therapy in Emerging Therapies in Allergic Disease, S. McDonald. (Ed). Immunol and Allergy Clin N Am 2004;24:551-68
32. Holgate S, Casale T, Wenzel S, et al. The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. J Allergy Clin Immunol 2005;115:459-65
33. MacGlashan D Jr, Lichtenstein LM, McKenzie-White J, et al. Upregulation of FcepsilonRI on human basophils by IgE antibody is mediated by interaction of IgE with FcepsilonRI. J Allergy Clin Immunol 1999;104:492-8
34. MacGlashan DW Jr, Bochner BS, Adelman DC, et al. Down-regulation of fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol 1997;158:1438-45
35. Saini SS, MacGlashan DW Jr, Sterbinsky SA, et al. Down-regulation of human basophil IgE and FC epsilon RI alpha surface densities and mediator release by anti-IgE-infusions is reversible in vitro and in vivo. J Immunol 1999;162:5624-30
36. Prussin C, Griffith DT, Boesel KM, et al. Omalizumab treatment downregulates dendritic cell FcepsilonRI expression. J Allergy Clin Immunol 2003;112:1147-54
37. Plewako H, Arvidsson M, Petruson K, et al. The effect of omalizumab on nasal allergic inflammation. J Allergy Clin Immunol 2002;110:68-71
38. Beck LA, Marcotte GV, MacGlashan D, et al. Omalizumab-induced reductions in mast cell fce psilon RI expression and function. J Allergy Clin Immunol 2004;114:527-30
39. Kitaura J, Song J, Tsai M, et al. Evidence that IgE molecules mediate a spectrum of effects on mast cell survival and activation via aggregation of the FcepsilonRI. Proc Natl Acad Sci USA 2003;100:12911-16
40. Ong YE, Menzies-Gow A, Barkans J, et al. Anti-IgE (omalizumab) inhibits late-phase reactions and inflammatory cells after repeat skin allergen challenge. J Allergy Clin Immunol 2005;116:558-64
41. Djukanovic R, Wilson SJ, Kraft M, et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med 2004;170:583-93
42. Casale TB, Bernstein IL, Busse WW, et al. Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis. J Allergy Clin Immunol 1997;100:110-21
43. Adelroth E, Rak S, Haahtela T, et al. Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. J Allergy Clin Immunol 2000;106:253-9
44. Casale TB, Stokes Jr. Chapter 96. Anti IgE therapy. In: Adkinson NF, Middleton E, Casale TB, Stokes JR, editors. Middleton's allergy: Principles & practice. Mosby/Elsevier, Philadelphia, PA; 2009
45. Vichyanond P. Omalizumab in allergic diseases, a recent review. Asian Pac J Allergy Immunol 2011;29:209-19
46. Hamilton RG, Marcotte GV, Saini SS. Immunological methods for quantifying free and total serum IgE levels in allergy patients receiving omalizumab (xolair) therapy. J Immunol Methods 2005;303:81-91
47. Fox JA, Hotaling TE, Struble C, et al. Tissue distribution and complex formation with IgE of an anti-IgE antibody after intravenous administration in cynomolgus monkeys. J Pharmacol Exp Ther 1996;279:1000-8
48. Rambasek T, Kavuru MS. Omalizumab dosing via the recommended card versus use of the published formula. J Allergy Clin Immunol 2006;117:708-9
49. Package insert. xolair. Genentech, South San Francisco, CA; 2010. revised. Available at: Www.xolair.com 50. Casale TB. Experience with monoclonal antibodies in allergic mediated disease: Seasonal allergic rhinitis. J Allergy Clin Immunol 2001;108:S84-8
50. Grundmann SA, Hemfort PB, Luger TA, et al. Anti-IgE (omalizumab): A new therapeutic approach for chronic rhinosinusitis. J Allergy Clin Immunol 2008;121:257-8
51. Casale TB, Condemi J, LaForce C, et al. Effect of omalizumab on symptoms of seasonal allergic rhinitis: A randomized controlled trial. JAMA 2001;286:2956-67
52. Nayak A, Casale T, Miller SD, et al. Tolerability of retreatment with omalizumab, a recombinant humanized monoclonal anti-IgE antibody, during a second ragweed pollen season in patients with seasonal allergic rhinitis. Allergy Asthma Proc 2003;24:323-9
53. Chervinsky P, Casale T, Townley R, et al. Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis. Ann Allergy Asthma Immunol 2003;91:160-7
54. Lin H, Boesel KM, Griffith DT, et al. Omalizumab rapidly decreases nasal allergic response and FcepsilonRI on basophils. J Allergy Clin Immunol 2004;113:297-302
55. Hanf G, Noga O, O'Connor A, et al. Omalizumab inhibits allergen challenge-induced nasal response. Eur Respir J 2004;23:414-18
56. Nagakura T, Ogino S, Okubo K, et al. Omalizumab is more effective than suplatast tosilate in the treatment of japanese cedar pollen-induced seasonal allergic rhinitis. Clin Exp Allergy 2008;38:329-37
57. Ogino S, Nagakura T, Okubo K, et al. Re-treatment with omalizumab at one year interval for japanese cedar pollen-induced seasonal allergic rhinitis is effective and well tolerated. Int Arch Allergy Immunol 2009;149:239-45
58. . 59. Okubo K, Ogino S, Nagakura T, et al. Omalizumab is effective and safe in the treatment of japanese cedar pollen-induced seasonal allergic rhinitis. Allergol Int 2006;55:379-86
59. Okubo K, Nagakura T. Anti-IgE antibody therapy for japanese cedar pollinosis: Omalizumab update. Allergol Int 2008;57:205-9
60. Vignola AM, Humbert M, Bousquet J, et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy 2004;59:709-17
61. Kuehr J, Brauburger J, Zielen S, et al. Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J Allergy Clin Immunol 2002;109:274-80
62. Rolinck-Werninghaus C, Hamelmann E, Keil T, et al. The co-seasonal application of anti-IgE after preseasonal specific immunotherapy decreases ocular and nasal symptom scores and rescue medication use in grass pollen allergic children. Allergy 2004;59:973-9
63. Casale TB, Busse WW, Kline JN, et al. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol 2006;117:134-40
64. Berger W, Gupta N, McAlary M, et al. Evaluation of long-term safety of the anti-IgE antibody, omalizumab, in children with allergic asthma. Ann Allergy Asthma Immunol 2003;91:182-8
65. Busse W, Buhl R, Fernandez Vidaurre C,et al. Omalizumab and the risk of malignancy: Results from a pooled analysis. J Allergy Clin Immunol 2012;129:983,9.e6
66. . MacGlashan D Jr. Therapeutic efficacy of omalizumab. J Allergy Clin Immunol 2009;123:114-15
67. Eisner MD, Zazzali JL, Miller MK, et al. Longitudinal changes in asthma control with omalizumab: 2-year interim data from the EXCELS study. J Asthma 2012;49:642-8
68. Chipps B. Systemic reaction to omalizumab. Ann Allergy Asthma Immunol 2006;97:267
69. . Owens G, Petrov A. Successful desensitization of three patients with hypersensitivity reactions to omalizumab. Curr Drug Saf 2011;6:339-42
70. Lin RY, Rodriguez-Baez G, Bhargave GA. Omalizumab-associated anaphylactic reactions reported between January 2007 and June 2008. Ann Allergy Asthma Immunol 2009;103:442-5
71. Cruz AA, Lima F, Sarinho E, et al. Safety of anti-immunoglobulin E therapy with omalizumab in allergic patients at risk of geohelminth infection. Clin Exp Allergy 2007;37:197-207
72. Cox L, Platts-Mills TA, Finegold I, et al. American academy of allergy, asthma & immunology/american college of allergy, asthma and immunology joint task force report on omalizumab-associated anaphylaxis. J Allergy Clin Immunol 2007;120:1373-7
73. . Cox L, Lieberman P, Wallace D, et al. American academy of allergy, asthma & immunology/american college of allergy, asthma & immunology omalizumab-associated anaphylaxis joint task force follow-up report. J Allergy Clin Immunol 2011;128:210-12
74. . Dal Negro RW, Pradelli L, Tognella S, et al. Cost-utility of add-on omalizumab in difficult-to-treat allergic asthma in italy. Eur Ann Allergy Clin Immunol 2011;43:45-53
75. . Menzella F, Facciolongo N, Piro R, et al. Clinical and pharmacoeconomic aspects of omalizumab: a 4-year follow-up. Ther Adv Respir Dis 2012;6:87-95
76. Casale TB. Prous Science. Omalizumab: an effective anti-IgE treatment for allergic asthma and rhinitis. Drugs Today (Barc) 2004;40:367-76
77. Humbert M, Boulet LP, Niven RM, et al. Omalizumab therapy: patients who achieve greatest benefit for their asthma experience greatest benefit for rhinitis. Allergy 2009;64:81-4